Generic Lovenox Battle Heats Up With Amphastar’s ANDA Approval
Executive Summary
Momenta Pharmaceuticals and Sandoz have enjoyed approximately 14 months of de facto generic exclusivity on Sanofi’s anticoagulant Lovenox (enoxaparin), but faced with the imminent threat of competition they are trying to maintain their hold on the market through patent litigation.
You may also be interested in...
Momenta And Sandoz Pay $120m To Settle Enoxaparin Suit
Momenta and Sandoz must hand over $120m between them to a range of enoxaparin purchasers following final approval of a settlement agreement resolving claims the pair unfairly conspired to block further generic competition in the US to Sanofi’s Lovenox blood-thinner.
Amphastar Will Receive $59.9m In Momenta/Sandoz Settlement
The small generics company has talked about using the cash windfall from the expected settlement to fund clinical trials and possibly M&A.
Amphastar Poised To Receive $59.9m In Momenta/Sandoz Settlement
The small generic drug company has talked about using the cash windfall from the expected settlement to fund clinical trials and possibly M&A.